MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewGlobe Newswire•17/09/2026•08:30 ET0 ShareWhiz InsightsGenerateNo content available.
